ATR 1072 in Participants With PRKAG2 Syndrome

计划入组 37 人 · 首次发布于 2026 年 7 月 31 日

PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy

计划入组 750 人 · 首次发布于 2017 年 5 月 16 日

PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

计划入组 65 人 · 首次发布于 2025 年 12 月 5 日

DNAJB1-PRKACA fusion kinase targeted peptide vaccine

RAG2 lentiviral vector-transduced autologous hematopoietic cells gene therapy (RAG2-SCID)

Atrium Therapeutics Secures FDA Clearance of IND for ATR-1072, First Disease-Modifying Therapy for PRKAG2 Syndrome

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb for Second Lead Compound in Cardiovascular RNA Collaboration

Cardiomyopathy Market Projected to Reach $20+ Billion by 2035 as Novel Therapies Advance Through Clinical Development